je.st
news
Tag: merck
Jennison Associates Sells 6,335,140 Shares of Merck & Co., Inc.
2015-12-13 12:37:24| Biotech - Topix.net
Jennison Associates cut its stake in shares of Merck & Co., Inc. by 16.0% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 6,335,140 shares of the company's stock after selling 1,205,526 shares during the period.
Tags: inc
associates
shares
sells
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA (pembrolizumab) Combination Trial
2015-12-10 12:30:08| Merck.com - Product News
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lillys cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Mercks KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types. Language: English read more
Tags: trial
combination
expand
adding
Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS (Infliximab), a Biosimilar of Remicade, in Korea
2015-12-07 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Samsung Bioepis Second Immunology Biosimilar Approved, to be Commercialized Under Partnership with Merck KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis Co., Ltd. has received approval of RENFLEXIS (infliximab), a biosimilar of the immunology medicine Remicade, by the Ministry of Food and Drug Safety (MFDS) in Korea. Merck will commercialize Samsung Bioepis RENFLEXIS in Korea as part of Mercks commercialization partnership with Samsung Bioepis to offer high-quality biosimilar alternatives to existing biologic medicines. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: korea
samsung
approval
receives
Morgan Stanley Analysts Give Merck KGaA (MRK) a a 92.00 Price Target
2015-12-06 23:48:49| Biotech - Topix.net
The firm currently has a a "sell" rating on the stock. Other equities research analysts have also issued research reports about the company.
Tags: price
give
target
morgan
Merck & Co., Inc. (MRK) Price Target Lowered to $65.00 at Argus
2015-11-30 07:37:30| Biotech - Topix.net
The firm presently has a "buy" rating on the stock. Argus' price target indicates a potential upside of 20.46% from the company's current price.
Sites : [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] next »